Asterias Biotherapeutics, Inc. (AST) EPS Estimated At $-0.11

July 14, 2018 - By Margaret Guttierez

Asterias Biotherapeutics, Inc. (NYSEAMERICAN:AST) Logo

Analysts expect Asterias Biotherapeutics, Inc. (NYSEAMERICAN:AST) to report $-0.11 EPS on August, 13.They anticipate $0.07 EPS change or 38.89 % from last quarter’s $-0.18 EPS. After having $-0.09 EPS previously, Asterias Biotherapeutics, Inc.’s analysts see 22.22 % EPS growth. It closed at $1.8 lastly. It is down 52.94% since July 14, 2017 and is downtrending. It has underperformed by 65.51% the S&P500.

Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapies in the fields of cell therapy and regenerative medicine. The company has market cap of $99.02 million. The firm develops therapeutic products in the areas of neurology and oncology. It currently has negative earnings. The Company’s clinical stage programs include AST-OPC1, a therapy derived from pluripotent stem cells that has completed a Phase I clinical trial for the treatment of thoracic spinal cord injuries; and that is in Phase I/IIa clinical trial for treating cervical spinal cord injuries, as well as for the treatment of multiple sclerosis and white matter stroke.

Asterias Biotherapeutics, Inc. (NYSEAMERICAN:AST) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.